Dr. Angelika Amon studies the molecular mechanisms that control cell growth and division, with a focus on the pathways that regulate chromosome segregation. She is currently the Kathleen and Curtis Marble Professor of Cancer Research at the MIT Koch Institute for Integrative Cancer Research and the Department of Biology.* Dr. Amon’s research also explores how errors in the processes of cellular growth and division lead to diseases such as cancer and Down syndrome and how they impact the aging process.
Prior to joining MIT in 1999, Dr. Amon completed a post-doctoral fellowship with Ruth Lehmann at the Whitehead Institute in Cambridge, Massachusetts and was subsequently named a Whitehead Fellow for three years. Her honors include the 2003 Alan T. Waterman Award, the 2007 Paul Marks Prize, the 2008 National Academy of Sciences Molecular Biology Award, and the 2013 Ernst Jung Prize for Medicine. In 2019, she was awarded the 2019 Breakthrough Prize in Life Sciences and the 2019 Vilcek Price in Biomedical Science. She is a member of the Howard Hughes Medical Institute, the National Academy of Sciences, the Austrian Academy of Science, and a Foreign Associate to EMBO. Dr. Amon received her B.S. and Ph.D. from the University of Vienna.
*Participation by Angelika Amon as an advisor to Dewpoint Therapeutics does not constitute or imply endorsement of Dewpoint Therapeutics by MIT or the Howard Hughes Medical Institute.